Hyperuricemia Resistant to a Xanthine Oxidase Inhibitor, Topiroxostat: a Case Report

被引：0
作者：
Takahide Kimura
Seiki Yamada
Masayuki Tanemoto
机构：
[1] International University of Health and Welfare,Division of Nephrology, Department of Internal Medicine
来源：
SN Comprehensive Clinical Medicine | / 4卷 / 1期
关键词：
Chronic kidney disease; Gout; Hyperuricemia; Xanthine oxidase;
D O I：
10.1007/s42399-021-01081-1
中图分类号：
学科分类号：
摘要：
Hyperuricemia is a common complication of chronic kidney disease. Gout is a clinical symptom of hyperuricemia, and lowering serum uric acid concentration (sUA) is recommended to prevent its recurrence. Febuxostat and topiroxostat are sUA-lowering agents, which are presumed to act on the same site of xanthine oxidase (XO), the rate-limiting enzyme for urate production. We present a case of gout where febuxostat but not topiroxostat lowered sUA. The different efficacy between them indicates that XO inhibitors are not interchangeable even among those acting on the same site of XO.
引用
收藏
相关论文
共 50 条
  • [21] Longan Seed Extract Reduces Hyperuricemia via Modulating Urate Transporters and Suppressing Xanthine Oxidase Activity
    Hou, Chien-Wei
    Lee, Ying-Chung
    Hung, Hsiao-Fang
    Fu, Hua-Wen
    Jeng, Kee-Ching
    AMERICAN JOURNAL OF CHINESE MEDICINE, 2012, 40 (05): : 979 - 991
  • [22] Experimental and clinical nephroprotection by the xanthine oxidase inhibitor febuxostat
    Steubl, Dominik
    Michel, Martin C.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2016, 389 (08) : 815 - 817
  • [23] Ellagic Acid Exerts Beneficial Effects on Hyperuricemia by Inhibiting Xanthine Oxidase and NLRP3 Inflammasome Activation
    Sun, Ze-Rui
    Liu, Hua-Rong
    Hu, Di
    Fan, Mao-Si
    Wang, Ming-Yue
    An, Meng-Fei
    Zhao, Yun-Li
    Xiang, Ze-Min
    Sheng, Jun
    JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 2021, 69 (43) : 12741 - 12752
  • [24] Anti-hyperuricemia effect of hesperetin is mediated by inhibiting the activity of xanthine oxidase and promoting excretion of uric acid
    An, Meng-Fei
    Shen, Chang
    Zhang, Shao-Shi
    Wang, Ming-Yue
    Sun, Ze-Rui
    Fan, Mao-Si
    Zhang, Li-Juan
    Zhao, Yun-Li
    Sheng, Jun
    Wang, Xuan-Jun
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [25] Cardio-renal protective effect of the xanthine oxidase inhibitor febuxostat in the 5/6 nephrectomy model with hyperuricemia
    Omizo, Hiroki
    Tamura, Yoshifuru
    Morimoto, Chikayuki
    Ueno, Masaki
    Hayama, Yuto
    Kuribayashi-Okuma, Emiko
    Uchida, Shunya
    Shibata, Shigeru
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [26] Renoprotective effect of the xanthine oxidoreductase inhibitor topiroxostat on adenine-induced renal injury
    Kamijo-Ikemori, Atsuko
    Sugaya, Takeshi
    Hibi, Chihiro
    Nakamura, Takashi
    Murase, Takayo
    Oikawa, Tsuyoshi
    Hoshino, Seiko
    Hisamichi, Mikako
    Hirata, Kazuaki
    Kimura, Kenjiro
    Shibagaki, Yugo
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2016, 310 (11) : F1366 - F1376
  • [27] Intestinal FXR deficiency induces dysregulation of xanthine oxidase and accounts for sex difference in hyperuricemia
    Bao, Ruixia
    Chen, Beibei
    Wang, Alexander
    Wang, Dan
    Pan, Jujie
    Chen, Qian
    Wu, Yuzheng
    Zhu, Zicheng
    Yu, Haiyang
    Zhang, Yi
    Wang, Tao
    FREE RADICAL BIOLOGY AND MEDICINE, 2025, 226 : 374 - 388
  • [28] A Drug-Drug Interaction Study of a Novel Selective Urate Reabsorption Inhibitor, SHR4640, and Xanthine Oxidase Inhibitor, Febuxostat, in Patients With Primary Hyperuricemia
    Wang, Chenjing
    Yu, Qing
    Jiang, Xin
    Deng, Yujie
    Sun, Feifei
    Li, Xin
    Tao, Ye
    Lin, Pingping
    Ma, Yaping
    Zhu, Yuxian
    Li, Chengqian
    Cao, Yu
    JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 63 (02) : 239 - 249
  • [29] 3,4-Dihydroxy-5-nitrobenzaldehyde (DHNB) is a potent inhibitor of xanthine oxidase: A potential therapeutic agent for treatment of hyperuricemia and gout
    Lue, Jian-Ming
    Yao, Qizhi
    Chen, Changyi
    BIOCHEMICAL PHARMACOLOGY, 2013, 86 (09) : 1328 - 1337
  • [30] Efficacy and Safety of Febuxostat, a Novel Nonpurine Selective Inhibitor of Xanthine Oxidase for the Treatment of Hyperuricemia in Kidney Transplant Recipients
    Tojimbara, T.
    Nakajima, I.
    Yashima, J.
    Fuchinoue, S.
    Teraoka, S.
    TRANSPLANTATION PROCEEDINGS, 2014, 46 (02) : 511 - 513
12345